PURINE NUCLEOSIDE PHOSPHORYLASE &NEW CHEMOTHERAPIES FOR LYMPHOMA &GRAFT REJECT
$0P41FY2000RRNIH
Yeshiva University, New York NY
Investigators
Linked publications & trials
Paper 15000707Paper 14976313Paper 14555254Paper 12693211Paper 12691754Paper 12667055Paper 12454462Paper 12405853Paper 12091724Paper 11980483Paper 11980480Paper 11910018Paper 11882463Paper 11827473Paper 11790140Paper 11786013Paper 11779360Paper 11754247Paper 11683881Paper 11563839Paper 11420138Paper 11294624Paper 11246743Paper 11238645Paper 11196887Paper 11170405Paper 11161303Paper 10858296Paper 10677240
Abstract
The following structures have been solved or datasets collected: apo-Guanylate Kinase: Hg MAD data at 2.0 A, four wavelengths. Structure has been solved by MAD phasing and the refinement at 1.8 A is in progress. ERA GTPase: SeMet MAD data at 3.2 A, four wavelengths. We were not able to solve for the 16 Se sites due to the low resolution and low signal/noise ratio. ERA GTPase: native data at 2.6 A. apo-Guanylate Kinase: native data at 1.8 A. ERA GTPase: Hg MAD data at 2.6 A, four wavelengths. MAD phases have a FOM of 0.60 before solvent flattening. Tracing is in progress.
View original record on NIH RePORTER →